TRMED Stock Overview

Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details

TRMED fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the Norwegian market

Makes less than USD$1m in revenue (NOK0)

Less than 3 years of financial data is available

Does not have a meaningful market cap (NOK613M)

My Notes

Capture your thoughts, links and company narrative

Thor Medical ASA Competitors

Hofseth BioCare

OB:HBC

NOK 631.0m

ArcticZymes Technologies

OB:AZT

NOK 687.4m

Nykode Therapeutics

OB:NYKD

NOK 943.1m

BerGenBio

OB:BGBIO

NOK 326.4m

Price History & Performance

Summary of share price highs, lows and changes for Thor Medical
Historical stock prices
Current Share Price	NOK 2.61
52 Week High	NOK 5.00
52 Week Low	NOK 0.85
Beta	0
1 Month Change	-37.78%
3 Month Change	154.88%
1 Year Change	74.00%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	30.63%

Recent updates

Shareholder Returns

	TRMED	NO Biotechs	NO Market
7D	-10.0%	-3.9%	-2.8%
1Y	74.0%	-73.8%	-0.8%

Return vs Industry: TRMED exceeded the Norwegian Biotechs industry which returned -73.8% over the past year.

Return vs Market: TRMED exceeded the Norwegian Market which returned -0.8% over the past year.

Price Volatility

Is TRMED's price volatile compared to industry and market?
TRMED volatility
TRMED Average Weekly Movement	25.8%
Biotechs Industry Average Movement	14.0%
Market Average Movement	5.0%
10% most volatile stocks in NO Market	10.9%
10% least volatile stocks in NO Market	2.6%

Stable Share Price: TRMED's share price has been volatile over the past 3 months compared to the Norwegian market.

Volatility Over Time: TRMED's weekly volatility has increased from 15% to 26% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	5	Jasper Kurth	www.thormedical.no

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.

Thor Medical ASA Fundamentals Summary

How do Thor Medical's earnings and revenue compare to its market cap?
TRMED fundamental statistics
Market cap	NOK 612.98m
Earnings (TTM)	-NOK 18.56m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-33.0x

P/E Ratio

Is TRMED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRMED income statement (TTM)
Revenue	NOK 0
Cost of Revenue	NOK 0
Gross Profit	NOK 0
Other Expenses	NOK 18.56m
Earnings	-NOK 18.56m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 26, 2025

Earnings per share (EPS)	-0.079
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did TRMED perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 01:54
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thor Medical ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution